160 related articles for article (PubMed ID: 22436453)
1. Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium.
Goossens ME; Buntinx F; Joniau S; Ackaert K; Ameye F; Billiet I; Braeckman J; Breugelmans A; Darras J; Dilen K; Goeman L; Kellen E; Tombal B; Van Bruwaene S; Van Cleyenbreuge B; Van der Aa F; Vekemans K; Van Poppel H; Zeegers MP
BMC Urol; 2012 Mar; 12():8. PubMed ID: 22436453
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial.
Goossens ME; Zeegers MP; van Poppel H; Joniau S; Ackaert K; Ameye F; Billiet I; Braeckman J; Breugelmans A; Darras J; Dilen K; Goeman L; Tombal B; Van Bruwaene S; Van Cleyenbreugel B; Van der Aa F; Vekemans K; Buntinx F
Eur J Cancer; 2016 Dec; 69():9-18. PubMed ID: 27814472
[TBL] [Abstract][Full Text] [Related]
3. Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.
Bryan RT; Pirrie SJ; Abbotts B; Maycock S; During V; Lewis C; Grant M; Bird D; Devall AJ; Wallace DMA; James ND; Billingham LJ; Zeegers MP; Cheng KK;
JAMA Netw Open; 2023 Oct; 6(10):e2337494. PubMed ID: 37847504
[TBL] [Abstract][Full Text] [Related]
4. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
5. Use of selenium in chemoprevention of bladder cancer.
Brinkman M; Buntinx F; Muls E; Zeegers MP
Lancet Oncol; 2006 Sep; 7(9):766-74. PubMed ID: 16945772
[TBL] [Abstract][Full Text] [Related]
6. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
7. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT.
Lotan Y; Goodman PJ; Youssef RF; Svatek RS; Shariat SF; Tangen CM; Thompson IM; Klein EA
J Urol; 2012 Jun; 187(6):2005-10. PubMed ID: 22498220
[TBL] [Abstract][Full Text] [Related]
9. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
10. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
Kurth K; Tunn U; Ay R; Schröder FH; Pavone-Macaluso M; Debruyne F; ten Kate F; de Pauw M; Sylvester R
J Urol; 1997 Aug; 158(2):378-84. PubMed ID: 9224307
[TBL] [Abstract][Full Text] [Related]
12. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
Sylvester RJ; Oosterlinck W; Holmang S; Sydes MR; Birtle A; Gudjonsson S; De Nunzio C; Okamura K; Kaasinen E; Solsona E; Ali-El-Dein B; Tatar CA; Inman BA; N'Dow J; Oddens JR; Babjuk M
Eur Urol; 2016 Feb; 69(2):231-44. PubMed ID: 26091833
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
[TBL] [Abstract][Full Text] [Related]
15. Do antioxidants prevent colorectal cancer? A meta-analysis.
Pais R; Dumitraşcu DL
Rom J Intern Med; 2013; 51(3-4):152-63. PubMed ID: 24620628
[TBL] [Abstract][Full Text] [Related]
16. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Lippman SM; Klein EA; Goodman PJ; Lucia MS; Thompson IM; Ford LG; Parnes HL; Minasian LM; Gaziano JM; Hartline JA; Parsons JK; Bearden JD; Crawford ED; Goodman GE; Claudio J; Winquist E; Cook ED; Karp DD; Walther P; Lieber MM; Kristal AR; Darke AK; Arnold KB; Ganz PA; Santella RM; Albanes D; Taylor PR; Probstfield JL; Jagpal TJ; Crowley JJ; Meyskens FL; Baker LH; Coltman CA
JAMA; 2009 Jan; 301(1):39-51. PubMed ID: 19066370
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.
Sabichi AL; Lee JJ; Grossman HB; Liu S; Richmond E; Czerniak BA; De la Cerda J; Eagle C; Viner JL; Palmer JL; Lerner SP
Cancer Prev Res (Phila); 2011 Oct; 4(10):1580-9. PubMed ID: 21881030
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
19. Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis.
Lykke MR; Nielsen TK; Ebbensgaard NA; Zieger K
Scand J Urol; 2015 Jun; 49(3):230-6. PubMed ID: 25731785
[TBL] [Abstract][Full Text] [Related]
20. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
Messing E; Kim KM; Sharkey F; Schultz M; Parnes H; Kim D; Saltzstein D; Wilding G
J Urol; 2006 Aug; 176(2):500-4. PubMed ID: 16813878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
